BioAge Labs, Inc. (BIOA)
| Market Cap | 1.06B +572.6% |
| Revenue (ttm) | 10.32M +611.0% |
| Net Income | -89.93M |
| EPS | -2.39 |
| Shares Out | 44.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,119,808 |
| Open | 22.37 |
| Previous Close | 22.62 |
| Day's Range | 22.37 - 23.82 |
| 52-Week Range | 4.07 - 24.93 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 49.50 (+108.33%) |
| Earnings Date | Aug 5, 2026 |
About BIOA
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular e... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for BIOA stock is "Buy." The 12-month stock price target is $49.5, which is an increase of 108.33% from the latest price.
News
BioAge Labs doses first participant in QUELL-CV trial of BGE-102
BioAge Labs (BIOA) announced that the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept clinical trial of BGE-102, a potent, structurally novel, orally available, brain-penetran...
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular ris...
BioAge Labs Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Lead oral NLRP3 inhibitor BGE-102 showed strong phase I efficacy and safety, with phase II cardiovascular data expected by year-end and ophthalmology results mid-next year. APJ agonists and collaborations with Novartis and Lilly expand the pipeline, supported by $385M cash runway into 2026.
BioAge Labs Transcript: Jefferies Global Healthcare Conference 2026
BGE-102, a novel NLRP3 inhibitor, showed strong biomarker reductions and excellent tolerability in phase I, with phase II cardiovascular and DME trials underway. The program is well-funded, with key data and potential phase III enablement expected by year-end.
BioAge Labs initiated with a Buy at Roth Capital
Roth Capital analyst Adam Walsh initiated coverage of BioAge Labs (BIOA) with a Buy rating and $36 price target The firm believes the company’s lead asset BGE-102, am NLRP3 program…
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for me...
BioAge Labs initiated with a Buy at BTIG
BTIG initiated coverage of BioAge Labs (BIOA) with a Buy rating and $40 price target BioAge is a clinical-stage biopharmaceutical company focused on treating disease related to human aging, the…
BioAge Labs Transcript: R&D Day 2026
BGE-102, an oral NLRP3 inhibitor, showed robust Phase I efficacy and safety, with up to 86% CRP reduction and strong CNS/retinal penetration. Phase II trials in cardiovascular risk and diabetic macular edema are underway, supported by a strong cash position and expert validation of the anti-inflammatory strategy.
BioAge Labs Slides: FY 2026
BioAge Labs has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 8, 2026.
BioAge Labs reports Q1 EPS (52c), consensus (63c)
Reports Q1 revenue $2.77M, consensus $1.08M. “The positive topline Phase 1 data we reported for BGE-102 in April reinforce our conviction that we have a potential best-in-class NLRP3 inhibitor: a…
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-...
BioAge Labs Quarterly report: Q1 2026
BioAge Labs has published its Q1 2026 quarterly earnings report on May 8, 2026.
BioAge Labs Earnings release: Q1 2026
BioAge Labs released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disea...
BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2
BioAge Labs (BIOA) reported results from the Phase 1 clinical trial of BGE-102, a novel, orally available, brain-penetrant small molecule NLRP3 inhibitor. The full dataset, which includes a newly anno...
BioAge Labs Transcript: Study result
Phase I results for BGE-102 showed up to 86% CRP reduction and strong safety in obese subjects, with most patients reaching CRP below 2 mg/L. The drug demonstrated potent inhibition of IL-1β and IL-6, strong CNS/ocular penetration, and supports advancement into phase II cardiovascular and ophthalmology trials.
BioAge Labs Press release: Study result
BioAge Labs issued a press release on April 21, 2026, disclosing material business information to investors.
BioAge Labs Proxy statement: Proxy filing
BioAge Labs filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
BioAge Labs Proxy statement: Proxy filing
BioAge Labs filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose ...
BioAge Labs Slides: Corporate presentation
BioAge Labs has posted slides in relation to its latest quarterly earnings report, which was published on April 20, 2026.
BioAge Labs Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is advancing BGE-102, a novel NLRP3 inhibitor, into phase I and II trials for cardiovascular and ophthalmology indications, with promising early efficacy and safety data. Strong financials and sector interest support a robust pipeline, including APJ agonists for obesity.
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
EMERYVILLE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for ...
BioAge Labs initiated with a Buy at Needham
Needham initiated coverage of BioAge Labs (BIOA) with a Buy rating and $50 price target The firm is “bullish” on the company’s lead asset BGE-102, an oral, NLRP3 inhibitor in…
BioAge Labs files automatic mixed securities shelf
16:23 EDT BioAge Labs (BIOA) files automatic mixed securities shelf